Syndax raises $250M via 2.25% convertible notes due 2031; conversion price at 35% premium

Syndax Pharmaceuticals Inc

$250M aggregate principal, 2.25% interest, semiannual payments starting Dec 15, 2026, maturing June 15, 2031.
Net proceeds ~$243M after fees; used for general corporate purposes including R&D, commercialization, and BD.
Initial conversion rate 40.3894 shares per $1,000 principal, equivalent to ~$24.76/share (35% premium over June 3 closing).
Notes are senior unsecured; callable only after June 20, 2029 if stock price exceeds 130% of conversion price.
Conversion permitted upon certain stock price thresholds or specified corporate events; company may settle in cash, stock, or mix.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Syndax Pharmaceuticals Inc issued convertible note to certain investors for $250.0 million aggregate principal amount.

Security: convertible note
Purchaser: certain investors
Consideration: $250.0 million aggregate principal amount

Exact text from the filing

the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Syndax Pharmaceuticals Inc entered into Indenture with U.S. Bank Trust Company, National Association valued at $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (effective 2026-06-03).

Action: entry
Agreement: notes offering
Counterparty: U.S. Bank Trust Company, National Association
Value: $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
Effective: 2026-06-03

Exact text from the filing

On June 3, 2026, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into privately negotiated subscription agreements (the “ Subscription Agreements ”) with certain investors, pursuant to which the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “ Notes ”).

View on SEC.gov

226 equity issuances filed in the last 30 days. Browse all equity issuances →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001193125-26-256458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.